The study examines the use of next-generation checkpoints like LAG-3, TIM-3, TIGIT, IDO1, and VISTA to overcome resistance to CTLA-4/PD-1 inhibitors, particularly in GBM, where the immunosuppressive tumor microenvironment presents significant challenges. Here, PDCD1 is linked to glioblastoma.